ABSTRACT
Although it is an essential diagnostic tool, prostate needle core biopsies are prone to interobserver variability in diagnosis, and there may be differences in pathologists' practice patterns. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Immunohistochemistry (IHC) can be performed to aid in the diagnosis of prostate needle core biopsy specimens by confirming small foci of prostatic adenocarcinoma and limiting the overdiagnosis of nonneoplastic mimickers, yet interobserver variability is still problematic. 17, 18 There is abundant literature regarding interobserver variability with respect to diagnosis and Gleason scoring of prostate biopsy specimens, but there is minimal information Upon completion of this activity you will be able to:
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describing differences in practice patterns between pathologists in routine clinical practice. A recent study has shown varying cancer detection rates between urology practices within a single state in the United States. 12 Only two prior studies have directly analyzed pathologists' diagnostic practice patterns within a single institution, in which the authors described significant variation in the frequency of the diagnosis of prostatic adenocarcinoma between individual pathologists in community hospital groups located in Canada and the Philippines. 4, 5 These studies were limited by small sample sizes and non-US populations, and they may not be generalizable to larger practice settings. In addition, evidence suggests that there is inconsistency in the utilization of IHC in prostate biopsy specimens, 6, 7 which may lead to diagnostic differences and variable health care costs. However, metrics to evaluate the overuse and underuse of ancillary testing in prostate needle core biopsy specimens have not been established. 6, 7 In addition, a cost analysis of IHC stain usage comparing pathologist practice patterns is absent from the relevant literature.
The purpose of this study was to determine whether pathologists at a single tertiary care institution vary in diagnostic practice patterns and IHC usage within prostate needle core biopsy specimens. In addition, the impact of the differences in IHC usage on health care costs was analyzed.
Materials and Methods
The study was performed with the consent of our institutional review board and complied with guidelines (protocol 2014C0114). We retrospectively obtained electronic pathology reports and clinic notes for consecutive men who underwent prostate needle core biopsies between July 1, 2008, and June 30, 2013, at our large academic tertiary care institution. The biopsy samples were collected using an 18-gauge biopsy gun with end-fire or side-fire ultrasound probes and submitted by 15 urologists. Our institution is composed of two campuses: main campus and east campus. Among the nine pathologists included in the study, two pathologists (pathologists 1 and 9) were genitourinary fellowship trained. Pathologists 1 to 4 and 6 to 9 practiced at the main campus, while pathologist 5 practiced at the east campus. Cases signed out at the main campus had subspecialty sign-out, while those signed out at the east campus had general sign-out. There is no mandatory pre-sign-out consensus or quality assurance for any campus, irrespective of diagnosis. Pre-sign-out consultation is performed at the preference of the sign-out pathologist and can use pathologists from either campus, with multiple pathologists on site several days a week at either location.
Biopsy tissue was subsequently embedded with paraffin and sliced into six levels. Levels 1, 2, 4, and 5 were stained with H&E. Levels 3 and 6 were reserved for IHC as needed after review of the H&E-stained levels. IHC was performed using a cocktail of two basal cell markers (p63 and HMWK or CK5) and α-methylacyl-CoA racemase. The following data were collected electronically for each biopsy specimen: prostate-specific antigen (PSA) values within 6 months prior to biopsy, patient age, case sign-out pathologist, number of separately labeled and submitted containers (parts) per case, worst diagnosis per case, highest Gleason grade for cases containing prostatic adenocarcinoma, and the total number of IHC stains performed per case (inclusive of only the IHC cocktail previously mentioned).
Cases signed out by pathologists with fewer than 100 total cases over the review period were pooled by campus. Campus groupings that did not meet a minimum of 100 cases were excluded from the study. Four pathologists (pathologists 6-9) were pooled and four others (pathologists 10-13) were excluded due to failure to meet case minimum requirements when pooled. One pathologist (pathologist 5) was excluded from certain analyses due to statistical differences in patient PSA.
Cases were classified into one of four possible diagnoses: (1) nonneoplastic, (2) high-grade intraepithelial neoplasia (HGPIN), (3) atypical small acinar proliferation (ASAP), or (4) adenocarcinoma. The diagnosis per biopsy that was recorded was the most malignant diagnosis in any separately submitted part (adenocarcinoma > ASAP > HGPIN > nonneoplastic). Adenocarcinoma cases were subclassified for analysis: Gleason score 6 or less (group 1), Gleason score 3 + 4 = 7 (group 2), Gleason score 4 + 3 = 7 (group 3), Gleason score 8 (group 4), or Gleason score 9 or more (group 5).
Gleason scores were compared between pathologists. Pathologists from the Gleason score group with the most disparate results were subsequently analyzed to identify the largest positive outlier. A blinded review of all cases in this category was performed by a fellowship-trained genitourinary pathologist (D.L.Z.) to reassess for discrepant Gleason scores. Discrepant cases were subsequently reviewed by a second blinded, fellowship-trained genitourinary pathologist (A.V.P.), and Gleason scores from the second pathologist were recorded for comparison with the original score.
The Ohio Medicare 2016 rate for the Current Procedural Terminology code 88344 ($162.08) was used to calculate total professional and technical fees for IHC.
K-sample equality-of-medians test was used to determine the equality of PSA between pathologist patient cohorts. A one-way analysis of variance (ANOVA) was used to determine the equality of mean age between pathologist patient cohorts. 
Results

Cohort
The final cohort included in the study was composed of 1,777 prostate needle core biopsy specimens from 1,568 patients over the study period. These cases were signed out by nine pathologists. Pathologists 1 to 4 and 6 to 9 were from the main campus, and pathologist 5 was from the east campus. Five pathologists (2, 4, 5, 6, and 7) had been in practice for more than 20 years, while the other four pathologists (1, 3, 8, and 9) had less than 10 years of experience. Pathologists 1 and 9 were genitourinary surgical pathology fellowship trained (diagnosed 46.3% of the cohort). All patient cohorts stratified by case pathologist were not statistically different with respect to patient age (mean, 61.3 years; P = .156). The PSAs of patient populations per pathologist were not statistically different (median, 5.59 ng/mL; P = .136) after excluding the single pathologist from the east campus (pathologist 5) with an outlying patient cohort (median, 6.87 ng/mL; P = .045). A subset of the original patient cohort (n = 1,669) was used to assess variability in diagnostic practice patterns after excluding pathologist 5. There was no significant difference in patient PSAs per pathologist within nonneoplastic cases (median, 5.20 ng/mL; P = .103), inclusive of pathologist 5, and as such, pathologist 5 was included in the comparison of IHC usage per pathologist within the subset of nonneoplastic cases (n = 671).
The total cohort had the following rates of diagnosis: 4.9% ASAP, 5.3% HGPIN, 38.6% nonneoplastic, and 51.2% adenocarcinoma.
Diagnostic Practice Patterns
Diagnostic reporting varied significantly between pathologists both with and without pathologist 5. Excluding pathologist 5, diagnostic reporting was ASAP, 2.0% to 8.0%; HGPIN, 2.0% to 8.5%; nonneoplastic, 30.2% to 48.3%; and adenocarcinoma, 46.2% to 55.3% (P < .001) ❚Table 1❚. Pathologist 1 had a lower rate of nonneoplastic diagnosis (30.2%; SPR = -6.36), while pathologist 2 had a higher rate (48.3%; SPR = 5.23) than the expected rate for the cohort. Conversely, pathologist 1 had a higher rate of HGPIN diagnosis (8.5%; SPR = 5.22), while pathologist 2 had a lower rate (2.0%; SPR = -3.84) than the expected rate for the cohort. The rates of ASAP and adenocarcinoma diagnoses were not statistically different from the expected rates for the cohort for any individual pathologist.
Gleason score reported for cases with adenocarcinoma varied significantly between pathologists (Gleason score ≤6, 34.9%-49.0%; Gleason score 3 + 4 = 7, 21.2%-40.0%; Gleason score 4 + 3 = 7, 6.9%-30.3%; Gleason score 8, 4.5%-12.0%; Gleason score ≥9, 0.0%-13.1%; P < .001) ❚Figure 1❚. Pathologist 5 was not a significant outlier and was therefore included. Gleason score 4 + 3 = 7 contained the greatest degree of variation between pathologists. Pathologist 3 was the largest positive outlier with 30.3% of adenocarcinoma cases reported as Gleason score 4 + 3 = 7 (SPR = 4.11). A blinded review of pathologist 3's cases with Gleason score 4 + 3 = 7 revealed discrepant Gleason scores in nine (45.0%) of 20 cases, with 15.0% having a higher score and 30.0% having a lower score. Two cases were discrepant by more than one grade group (one case was 3 + 3 = 6 upon review, and one case was 4 + 5 = 9 upon review) ❚Image 1❚. Five of the discrepant cases had follow-up radical prostatectomies. Four cases were lower grade upon review and lower grade at prostatectomy (all pT2cN0). One case was higher grade upon review and was 4 + 3 = 7 with tertiary 5 pattern and extraprostatic extension at prostatectomy (pT3aN0).
IHC Usage Practice Patterns
The mean number of parts per case was 10, and the percentage of cases with 10 or more cores was 97.4% The percentage of cases with IHC usage for the entire cohort varied significantly by diagnosis from 11.8% in nonneoplastic cases to 92.9% in ASAP cases (P < .001) ❚Figure 2❚. IHC usage also varied significantly by Gleason score (P < .001) ❚Table 2❚. IHCs were used in 31.7% of adenocarcinoma cases, with the highest usage rate for Gleason score 3 + 3 = 6 (53.4%, 1.3 per case) and lowest usage rate for Gleason score 9 or more (9.8%, 0.2 per case).
The percentage of cases with IHC usage per pathologist (19.7%-55.6%, P < .001) and the mean number of IHCs performed per case per pathologist (0.3-1.2, P < .001) differed significantly ❚Table 3❚. Pathologist 5 had a higher proportion of cases with IHC usage compared with the cohort (55.6%; SPR = 6.34). To adjust for differing rates of diagnoses and varying patient populations between pathologists in the evaluation of IHC usage, the subset of nonneoplastic biopsy specimens was analyzed ❚Figure 3❚. Pathologist 5 remained an outlier in IHC usage, with a mean of 0.6 stains per case performed in 34.6% of nonneoplastic biopsy specimens (SPR = 3.43), compared with 0.3 stains per case performed in 11.8% of nonneoplastic biopsy specimens for all other pathologists.
Based on the mean IHCs used per nonneoplastic case, pathologist 5 charged an average of $94.01 per case, compared to $45.38 per case among all other pathologists. 
Discussion
A retrospective analysis of prostate needle core biopsy diagnostic practice patterns among pathologists at a tertiary care institution is absent from the literature. Most quality assurance analyses of prostate biopsy diagnoses have assessed interobserver variability, which may not reflect clinical practice. [8] [9] [10] [11] [19] [20] [21] In addition, patterns of IHC utilization in diagnosing prostate needle core biopsy specimens are poorly studied. We analyzed data from routine clinical practice at a large tertiary care center in the United States to identify outlying practice patterns among pathologists with respect to diagnosis and IHC usage. Furthermore, our results allow for future comparisons to other tertiary care academic centers for interinstitutional analyses.
In prostate needle core biopsy specimens, rates of overall diagnostic categories at our institution were similar to the published literature from tertiary care centers (HGPIN, 5% vs 4%-12%; ASAP, 5% vs 6%-7%; nonneoplastic, 39% vs 30%-45%; adenocarcinoma, 51% vs 45%-52%). 6, 16 As prostate biopsy cases were distributed randomly among the pathologists at our institution, diagnostic rates should be similar. However, we demonstrated significant variation in diagnostic reporting despite statistically similar patient cohorts with respect to age and PSA. Specifically, two outlying practice patterns were ❚Figure 1❚ Gleason score reporting by case pathologist. Reporting varied significantly (P < .001). Pathologist 5 was excluded due to differences in prostate-specific antigen compared with the remainder of the cohort.
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Shah et al / Pathologists' imPact on Prostate BioPsy rePorting identified: (1) lower rates of nonneoplastic diagnoses with a higher rate of HGPIN and, conversely, (2) higher rates of nonneoplastic diagnoses with a lower rate of HGPIN. Although previous interobserver variability analyses have shown discordance in ASAP reporting, we did not observe differing rates in this diagnostic category. 10, 22, 23 It is reassuring that the rate of diagnoses with the highest clinical impact, adenocarcinoma and ASAP, had no statistically significant variability between pathologists at our institution.
A subset of interobserver variability studies found substantial agreement between pathologists for the main diagnostic categories. 24, 25 In addition, the focus of prior interobserver variability analyses was on the cohort, and these investigations did not assess for individual outliers. Two previous reports have evaluated the impact of the pathologist on prostate biopsy diagnosis during routine clinical practice at a single institution. In a small cohort of 182 prostate biopsies performed at a community hospital in Ontario, Newell et al 5 demonstrated that diagnostic reporting varied significantly between three pathologists (HGPIN, 6%-17%; ASAP, 6%-22%; nonneoplastic, 8%-29%; and adenocarcinoma, 54%-69%). A larger study (n = 656) conducted at a medical center in the Philippines investigated the differences in ASAP reporting rates between genitourinary pathologists and general surgical pathologists. 4 Genitourinary pathologists had lower rates of ASAP diagnosis, but variation between ❚Image 1❚ Prostate biopsy specimens diagnosed as Gleason score 4 + 3 = 7 by the farthest outlier (H&E). A-C, Re-review diagnosis was 3 + 3 = 6. A, Low power (×4). B, Well-formed glands representing 3 + 3 = 6 (×20). C, Area of crush that could be interpreted as a higher grade (×20). D-F, Re-review diagnosis was 4 + 4 =8 with pT3aN0 at prostatectomy. D, Low power (×2). E, Sheets of fragmented tumor with glandular differentiation (×4). F, Higher power showing cribriform spaces (×10).
individual pathologists was not reported, and the diagnostic analysis was limited to ASAP only.
In addition to diagnostic categorization, we demonstrated significant variation in Gleason scoring between pathologists (Gleason score ≤6, 35%-49%; 3 + 4 =7, 21%-40%; 4 + 3 = 7, 7%-30%; 8, 5%-12%; ≥9, 0%-13%). To our knowledge, only one other publication has described variability of Gleason scoring within clinical practice. Newell et al 5 reported discrepancies in Gleason scoring among pathologists (Gleason score 6, 12%-58%; 7, 36%-67%; and 8-9, 6%-27%); however, a statistical analysis to identify outliers was not performed. In our investigation, the Gleason score 4 + 3 = 7 category had the widest distribution of cases between pathologists; three of the nine pathologists were outliers in this category. A blinded review of cases from the highest positively outlying pathologist in the Gleason score 4 + 3 = 7 category showed that prostate biopsy specimens were both overgraded and undergraded. Overgrading cases as Gleason score 4 + 3 = 7 is clinically relevant as it excludes patients from receiving active surveillance or brachytherapy. Institutions should consider analyzing pathologists' practice patterns to identify outliers and errors in prostate biopsy diagnosis that may affect clinical management. The overall rate of IHC usage in prostate needle core biopsy specimens at our institution was slightly lower than that reported by other tertiary care centers (29% vs 36%-39%). 7, 16 In addition, our institution used IHCs in a greater proportion of adenocarcinoma cases and in a lower proportion of nonneoplastic cases relative to other large institutions (HGPIN, 6% vs 11%-12%; ASAP, 18% vs 18%-24%; nonneoplastic, 17% vs 22%-30%; and adenocarcinoma, 59% vs 35%-48%). 7, 16 We demonstrated that a single outlier existed in our cohort, while the remaining pathologists had statistically similar rates of IHC usage. Even after adjusting for differing rates of diagnoses and varying patient populations, one pathologist remained an outlier with IHC usage in 23% more cases than all other pathologists. The outlier ordered twice as many IHCs per case as the cohort for an additional cost of $49 per nonneoplastic case, a practice pattern difference of approximately $33,000 across all nonneoplastic biopsy specimens. Three other studies have compared IHC usage between pathologists in the clinical practice setting. The first two compared nongenitourinary pathologists with genitourinary pathologists and determined that genitourinary pathologists used IHC less frequently than their counterparts. 4, 6 A recent report identified variable IHC usage between 16 individual pathologists at an academic tertiary care center within the United States. 7 Al Diffalha et al 7 determined that the rate of IHC usage per pathologist varied between 23% and 50%, comparable to the range of 20% to 56% at our institution. Statistical analyses to identify individual outliers in IHC usage were not performed in any of the aforementioned reports. 4, 6, 7 Since national guidelines for best practice applications of ancillary IHC in prostate biopsy diagnostics have only been established within the past few years, intrainstitutional analysis of outlying practice patterns may help minimize variability in resource utilization. 6, 7, 26, 27 An efficient use of IHCs in diagnosing prostate biopsy specimens could have important cost-saving benefits. In conclusion, in our investigation, the case pathologist significantly affected both prostate biopsy diagnosis and IHC workup. We identified outlying diagnostic patterns involving an inverse relationship between rates of nonneoplastic and HGPIN diagnoses. In addition, there was variability in Gleason scoring between pathologists during routine clinical practice, most notably with score 4 + 3 = 7. Finally, we observed significant variation in IHC utilization among pathologists, affecting patient care expenditures. Evaluation for outlying practice patterns in prostate biopsy cases is recommended to provide consistent and efficient patient care.
